[Long-term effects of HBV treatment Peg-IFN alfa-2a alone or combined with lamivudine].
The long-term outcomes showed a special place of IFN alfa-2a in therapy of chronic hepatitis B. Multivariate analysis revealed that patients who received 48 weeks treatment PegIFN-alfa-2a with reduction of serum ALT level and suppression of HBV-DNA replication will have a chance to keep this effect in the future. The results of long term follow-up showed that IFN alfa-2a improves prognosis in terms of reduction of progression to cirrhosis and hepatocellular carcinoma.
Pogorzelska
Joanna
J
Klinika Obserwacyjno-Zakaźna, Akademia Medyczna w Białymstoku. joannapogo@yahoo.com
Flisiak
Robert
R
D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006513:Hepatitis B e Antigens / Q000187:drug effects; D006515:Hepatitis B virus / Q000187:drug effects; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D019259:Lamivudine / Q000627:therapeutic use*; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine